Clinical Trials on Lung Cancer (NSCLC)

Total 96146 results

Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

NSCLC

China
Guangdong Association of Clinical Trials

Unknown

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Nsclc
Allist Pharmaceuticals, Inc.

Unknown

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

NSCLC
Henan Cancer Hospital
Cttq

Unknown

Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer

NSCLC

China
Hutchison Medipharma Limited

Completed

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

NSCLC

China
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study (IMAHTEP)

NSCLC

France
HiberCell, Inc.

Completed

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NSCLC

United States, Germany
Pierre Fabre Medicament
Pierre Fabre Pharma GmbH

Completed

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

NSCLC

Germany
Nanfang Hospital of Southern Medical University

Unknown

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

NSCLC

China
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Henan Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study (NSCLC)

Nsclc
Tang-Du Hospital

Not yet recruiting

Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer (pcwaintrl)

NSCLC
University Hospital, Brest

Completed

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer (IMMUNOBZH)

NSCLC

France
Afﬁliated Hospital of North Sichuan Medical College
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

NSCLC

China
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Shanghai Chest Hospital

Not yet recruiting

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

NSCLC, Stage III
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Staging IV NSCLC

China
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
Mylan Pharmaceuticals Inc

Completed

MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

NSCLC Stage IV

Turkey, Taiwan, Vietnam, Croatia, India, Russian Federation, Spain, Hungary, Bosnia and Herzegovina, Ukraine, Poland, Romania, Belarus, Bulgaria, Georgia, Italy, Philippines
Instituto do Cancer do Estado de São Paulo

Unknown

Factors Determining the Prognosis in NSCLC Stage IV (LUPROG)

NSCLC Stage IV

Brazil
Yuhan Corporation
The Korean Academy of Tuberculosis and Respiratory Diseases

Recruiting

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

NSCLC

Korea, Republic of
Peking University Cancer Hospital & Institute
Geneplus-Beijing Co. Ltd.

Recruiting

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (MRDinS3LC)

NSCLC

China
Hunan Province Tumor Hospital

Not yet recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NSCLC

China
Shanghai Chest Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

NSCLC

China
Oslo University Hospital
St. Olavs Hospital

Recruiting

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients (Oncomabs)

NSCLC

Norway
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NSCLC
Kura Oncology, Inc.

Withdrawn

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NSCLC

United States
Qian Chu

Completed

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NSCLC

China
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE)

NSCLC

China
Shanghai Chest Hospital

Unknown

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

NSCLC

China
GlobeImmune
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

NSCLC

United States
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
AIO-Studien-gGmbH
Bristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaborators

Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)

Small-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

Germany
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) (GALILEO)

NSCLC Stage IV | ALK Gene Mutation | ALK Sensitizing Mutation

Italy
Fudan University

Unknown

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

NSCLC Patients

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer

Stage I NSCLC

China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

NSCLC, Stage III

China
Hasselt University
Ziekenhuis Oost-Limburg

Completed

Metabolomics Predict Therapy Response (PROLUNG)

NSCLC, Stage IIIA

Belgium
Fudan University

Unknown

Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy (NSCLC)

NSCLC | Chemoradiotherapy | ctDNA

China
KangLaiTe USA

Terminated

Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

Stage IV NSCLC

United States
Indiana University

Recruiting

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

NSCLC, Stage III

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
Microbio Co Ltd

Recruiting

Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC

NSCLC Stage IV

Taiwan
Vastra Gotaland Region
AstraZeneca

Recruiting

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)

NSCLC, Stage I

Finland, Norway, Sweden
The Netherlands Cancer Institute
Bristol-Myers Squibb

Terminated

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

NSCLC, Stage IV

Netherlands
Intergroupe Francophone de Cancerologie Thoracique
Amgen

Active, not recruiting

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (LungKG12Ci)

Nsclc | KRAS P.G12C

France

3

Subscribe